Show simple item record

dc.contributor.authorDuane, Francesen
dc.date.accessioned2023-01-03T10:14:16Z
dc.date.available2023-01-03T10:14:16Z
dc.date.issued2023en
dc.date.submitted2023en
dc.identifier.citationK. Nugent, E. Quinlan, S. Cleary, H. O'Driscoll, C. Rohan, J. Trousdell, J. Williams, M. Dunne, O Mc Ardle*, F.K. Duane*, Implementation of 26 Gy in five fractions over 1 week adjuvant radiotherapy for breast cancer: Prospective report of acute skin toxicity and consideration of resource implications, The Breast, 67, 2023, 55-61-en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.description.abstractPurpose: In March 2020, a 1-week adjuvant breast radiotherapy schedule, 26 Gy in 5 fractions, was adopted to reduce the risk of COVID19 for staff and patients. This study quantifies acute toxicity rates and the effect on linac capacity. Materials and Methods: This is a report of consecutive patients receiving ultrafractionated breast radiotherapy (+/- sequential boost) Mar-Aug 2020. Virtual consultations assessed acute skin toxicity during treatment and weeks 1, 2, 3 and 4 post treatment using CTCAE V5 scoring criteria. The number of linac minutes saved was estimated accounting for boost and DIBH use. Results: In total,128/135 (95%) patients, including 31/33 boost patients, completed at least 3/5 assessments. 0/128 (0%) reported moist desquamation not confined to skin folds or minor bleeding (Grade 3). 41/128 (32%) reported brisk erythema, moist desquamation confined to skin folds or breast swelling (Grade 2), 62/128 (48%) reported faint erythema or dry desquamation (Grade 1) as their worst skin toxicity, with the remaining 20% reporting no skin toxicity. The highest prevalence of grade 2 toxicity occurred week 1 following treatment (20%), reducing to 3% by week 4. There was no difference in toxicity between those who received a boost versus not (p= 1.00). Delivering this schedule to 135 patients over six months saved 21,300 linac minutes and 1485 hospital visits compared to a 3-week schedule. Conclusion: Rapidly implementing ultrahypofractionated breast radiotherapy is feasible and acute toxicity rates are acceptable even when followed by boost.en
dc.format.extent55-61en
dc.language.isoenen
dc.relation.ispartofseriesThe Breasten
dc.relation.ispartofseries67en
dc.rightsYen
dc.subjectbreast canceren
dc.subjectadjuvant radiotherapyen
dc.subjectultrafractionationen
dc.subjectacute toxicityen
dc.subjectresource implicationsen
dc.titleImplementation of 26 Gy in five fractions over 1 week adjuvant radiotherapy for breast cancer: Prospective report of acute skin toxicity and consideration of resource implicationsen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/fduaneen
dc.identifier.rssinternalid249858en
dc.identifier.doihttps://doi.org/10.1016/j.breast.2022.12.008en
dc.rights.ecaccessrightsopenAccess
dc.relation.doihttps://doi.org/10.1016/j.breast.2022.12.008en
dc.relation.citesCitesen
dc.subject.TCDThemeCanceren
dc.subject.TCDTagBREAST CANCERen
dc.subject.TCDTagRadiotherapyen
dc.identifier.orcid_id0000-0001-7838-5957en
dc.status.accessibleNen
dc.identifier.urihttp://hdl.handle.net/2262/101925


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record